Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder
Part of paid clinical trials in New York, New York.
- Sponsor
- State University of New York - Upstate Medical University
- Study ID
- NCT06006637
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 8 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cognilum TM: Light Treatment Condition — DEVICEThe children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
Study Details
This study will consist of a randomized, double-blind, sham-controlled clinical trial at SUNY Upstate Medical University and Mt. Sinai Medical Center with 80 autistic children evaluating the effects of transcranial photobiomodulation (tPBM) on multiple clinically validated scales.
Key Dates
- Start date
- Oct 17, 2023
- Status verified
- Dec 2024
- Primary completion
- Aug 15, 2026
- Completion
- Aug 15, 2026
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: CognilumTMDuring the study participants will be wear the transcranial photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
- Sham Comparator: Sham controlDuring the study participants will wear the transcranial photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
Primary Outcome Measure
Childhood Autism Rating Scale, Second edition [ Time Frame: 10 weeks ]
Central Contacts
- William E Sullivan, PhD315-464-3932
- Henry S Roane, PhD315-464-3555
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mt. Sinai Medical Center | New York | New York | 10029 | Catherine Sancimino, PhD |
| Golisano Center for Special Needs | Syracuse | New York | 13210 |
Find similar trials in New York, NY
By condition
By specialty
Related Studies
- Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)PHASE2 · Recruiting · Montefiore Medical Center · New York, New York
- Longitudinal Study of Neurogenetic DisordersRecruiting · Columbia University · New York, New York
- FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York
- ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York